These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34176233)

  • 1. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
    Okuyama A; Boku N; Higashi T
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1482. PubMed ID: 34176233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
    Okuyama A; Nakamura F; Higashi T
    JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.
    Yoshida I; Tamura K; Miyamoto T; Shimokawa M; Takamatsu Y; Nanya Y; Matsumura I; Gotoh M; Igarashi T; Takahashi T; Aiba K; Kumagai K; Ishizawa K; Kurita N; Usui N; Hatake K
    In Vivo; 2019; 33(4):1355-1362. PubMed ID: 31280230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
    Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients.
    Okuyama A; Takemura Y; Sasaki M; Goto A
    Support Care Cancer; 2022 Jul; 30(7):5931-5937. PubMed ID: 35391572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
    Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
    Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
    Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
    Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
    Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
    Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.